Efficacy of clarithromycin as a protective agent in the methotrexate-induced pulmonary fibrosis model

Methotrexate is a cytotoxic agent used in leukemia, and several other cancer types and at lower doses in auto-inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis and psoriasis. Macrolide antibiotics are effective against gram-positive and Gram-negative bacteria. They have anti...

Full description

Saved in:
Bibliographic Details
Published in:Kardiochirurgia i torakochirurgia polska 2018-12, Vol.15 (4), p.209-212
Main Authors: Kalemci, Serdar, Akpınar, Orhan, Dere, Yelda, Sarıhan, Aydın, Zeybek, Arife, Tanriverdi, Özgür
Format: Article
Language:English
Subjects:
Ankylosing spondylitis
Anti-inflammatory agents
Cancer
Clarithromycin
Cytotoxicity
Dosage
Fibrosis
Gram-negative bacteria
Inflammatory diseases
Lung diseases
Macrolide antibiotics
MAP kinase
Methotrexate
Original Paper
Psoriasis
Pulmonary fibrosis
Rheumatoid arthritis
Rodents
Spondylitis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Methotrexate is a cytotoxic agent used in leukemia, and several other cancer types and at lower doses in auto-inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis and psoriasis. Macrolide antibiotics are effective against gram-positive and Gram-negative bacteria. They have anti-inflammatory activities as well. Clarithromycin is a macrolide with anti-inflammatory activity through blockage of the p38 MAPK signal cascade, which is involved in methotrexate-induced pulmonary toxicity. In this study, the efficacy of clarithromycin in protecting against pulmonary fibrosis was investigated in the rat model for methotrexate-induced pulmonary fibrosis. A total of 30 female rats were divided into three groups. Group I was administered intraperitoneal and intragastric saline; group II was administered oral 3 mg/kg methotrexate; and group III was administered oral 3 mg/kg methotrexate + intraperitoneal 200 mg/kg clarithromycin for 28 days. Histopathological analyses of the lung tissues were performed under light microscopy. Normal histopathological changes were observed in the control group. Pulmonary fibrosis was significantly higher in the methotrexate group than in the other groups ( < 0.005). Clarithromycin was shown to be effective in protecting against methotrexate-induced pulmonary fibrosis; further studies should be performed to determine the dosage and safety.
ISSN:1731-5530
1897-4252
DOI:10.5114/kitp.2018.80915